Skip to main content
Journal ArticleOPEN ACCESS

Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes

  • Caballero J
  • Dávila J
  • López-Pavía M
  • et al.
Therapeutic Advances in Hematology (2024) 15
DOI: 10.1177/20406207231218157
3Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background:Erythropoiesis stimulating agents (ESAs) are the first-line therapy in patients with lower-risk myelodysplastic syndromes (LR-MDS). Some predictive factors for ESAs response have been id...

Cite

CITATION STYLE

APA

Caballero, J. C., Dávila, J., López-Pavía, M., Such, E., Bernal, T., Ramos, F., … Díez Campelo;, M. (2024). Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes. Therapeutic Advances in Hematology, 15. https://doi.org/10.1177/20406207231218157

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free